Kevin Dunleavy

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remain

After accepting Sanofi's application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has signed off on the expansion, albeit nearly two months later than the original target date.

Following much opposition from drugmakers, Germany has scrapped its plan to install a program that would have reduced the price of branded pharmaceuticals in a variable structure,

With the passage of another year in the biz, and another slate of company earnings stacked up against one another, Fierce is finishing the 2025 tally by laying out the annual rankings of the top-paid CEOs among the industry's heavyweights.

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is ba

Eighteen months after Novo Nordisk purchased a plant in the

GSK and Spero Therapeutics have scor

What’s been Novo Nordisk's secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition.

Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to